What Makes BioMarin (BMRN) so Attractive
BioMarin Pharmaceutical (NASDAQ:BMRN) is one of the 17 biotechnology stocks with more than 50% upside.
As of February 12 closing, BioMarin Pharmaceutical (NASDAQ:BMRN) carried a moderately bullish analyst sentiment. Of the 15 analysts covering the stock, 10 assigned Buy ratings and 5 issued Hold ratings. With no Sell rating, the stock has a projected median 1-year price target of $88.29, implying more than 47% upside.
On February 6, Allison Bratzel from Piper Sandler reiterated her Overweight rating on BioMarin Pharmaceutical (NASDAQ:BMRN). The analyst reduced her price target on the stock from $122 to $84. Despite this downward revision, her estimates still imply upside potential of more than 40% from the prevailing level. Bratzel’s rating incorporates recent fourth-quarter pre-releases, which also prompted Piper Sandler to adjust its estimates and price targets for some commercial names.
BioMarin Pharmaceutical (NASDAQ:BMRN) develops and commercializes targeted therapies for life-threatening medical conditions and rare genetic diseases. Some of its major products include VIMIZIM, VOXZOGO, NAGLAZYME, and ALDURAZYME. The company operates in more than 70 countries and currently has several drugs in the development stage.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
3 Altcoins To Watch This Weekend | May 23 – 24
Top XRP Ledger Validator Says This Is a Must Read for All XRP Holders
Gold import duty hike threatens decade-low volumes for jewellery retailers in FY27, warns Crisil

Investor Demand for S&P 500 Downside Protection Plummets 75% Since March
